» Articles » PMID: 7461027

Comparison of the Serum Protein Binding of Maprotiline and Phenytoin in Uraemic Patients on Haemodialysis

Overview
Specialty Pharmacology
Date 1981 Jan 1
PMID 7461027
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The serum protein binding of maprotiline and phenytoin has been compared in a group of 22 uraemic patients receiving haemodialysis. Determination of protein binding was carried out in vitro using equilibrium dialysis at 37 degrees C and 14C-labelled drug. The mean percentage unbound maprotiline found in patients (10.0%, SD 2.5) was not significantly different from that obtained in healthy volunteers (mean 10.5%, SD 1.0). However, there was a significantly increased variability in binding in patients compared with healthy subjects. The mean percentage unbound phenytoin in the same patients (22.2%, SD 3.3) was significantly greater than that obtained in healthy control subjects (12.5%, SD 0.6). Although there was no correlation between maprotiline and phenytoin binding and serum concentrations of alpha 1-acid glycoprotein, there was a significant correlation between percentage unbound maprotiline and serum albumin concentrations. The findings indicate that the binding of this tricyclic antidepressant is essentially normal in uraemia, although there may be increased interindividual variability in the free fraction of drug.

Citing Articles

An Exploration of the Interplay Between Caffeine and Antidepressants Through the Lens of Pharmacokinetics and Pharmacodynamics.

Truong J, Abu-Suriya N, Tory D, Bahho R, Ismaiel A, Nguyen T Eur J Drug Metab Pharmacokinet. 2025; 50(1):1-15.

PMID: 39870954 PMC: 11802704. DOI: 10.1007/s13318-024-00928-x.


Pharmacological and psychological treatment of depression and anxiety among hemodialyzed patients - a review.

Cwiek A Postep Psychiatr Neurol. 2024; 33(2):98-102.

PMID: 39119547 PMC: 11304225. DOI: 10.5114/ppn.2024.141377.


Alteration of drug-protein binding in renal disease.

Reidenberg M, Drayer D Clin Pharmacokinet. 1984; 9 Suppl 1:18-26.

PMID: 6705423 DOI: 10.2165/00003088-198400091-00003.


Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Zini R, Riant P, Barre J, Tillement J Clin Pharmacokinet. 1990; 19(3):218-29.

PMID: 2203581 DOI: 10.2165/00003088-199019030-00005.

References
1.
Reidenberg M, Odar-Cederlof I, von Bahr C, Borga O, Sjoqvist F . Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med. 1971; 285(5):264-7. DOI: 10.1056/NEJM197107292850506. View

2.
Ehrnebo M, AGURELL S, JALLING B, BOREUS L . Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. Eur J Clin Pharmacol. 1971; 3(4):189-93. DOI: 10.1007/BF00565004. View

3.
Piafsky K, Borga O . Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation. Clin Pharmacol Ther. 1977; 22(5 Pt 1):545-9. DOI: 10.1002/cpt1977225part1545. View

4.
Shoeman D, AZARNOFF D . The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin. Pharmacology. 1972; 7(3):169-77. DOI: 10.1159/000136286. View

5.
Braithwaite R, Heard R, Snape A . Plasma protein binding of maprotiline in geriatric patients--influence of alpha1-acid glycoprotein [proceedings]. Br J Clin Pharmacol. 1978; 6(5):448P-449P. View